PCI Biotech progressing positively

Our portfolio company PCI Biotech reports important progress in their half year presentation of 2017. The progress especially applies for the fimaCHEM programme , with early promising signs of effect in Phase I. The study has also provided encouraging interim overall survival data averaging 15.6 months per end July 2017 (median 14.4 months), with 25% of the patients still being alive.

 

 

These promising results may be further strengthened by repeating the treatment. Safety for repeated treatment will be investigated in a Phase I extension study and the first patient in this study was treated in August. Regulatory interactions to clarify the fastest way to market and subsequent preparations for Phase II will run in parallel with the extension study, thereby minimising time to initiation of a potential pivotal Phase II study with repeated treatment.

 “After the rapid initiation of the fimaCHEM Phase I extension study, we now have full focus on effective completion of this study and the regulatory interactions to clarify fastest route to market.  We are also eagerly awaiting the initial results on overall T-cell responses from the fimaVACC Phase I study and will revert to the market as soon as these are available,” comments CEO Per Walday.

Clinical translation of the fimaVACC asset is progressing with tolerability being established and the initial results on overall T-cell responses from the study are expected to be available during 2H 2017.

The fimaNAc programme has showed positive progress and the research collaborations with RXi Pharmaceuticals and a top-10 pharma company have both entered into new stages during 2017.

The rights issue completed in Q1 2017 enables PCI Biotech to progress the fimaChem programme through regulatory interactions to determine the fastest way to market, as well as the Phase I extension study and other preparations for initiation of Phase II. The proceeds, together with a grant from the Norwegian Research Council, will also cover the clinical translation of the promising fimaVACC asset. The organisation will be strengthened with Dr Olivecrona as Chief Medical Officer (CMO) from October 2017.

 

 

Highlights
fimaCHEM

  • Encouraging interim overall survival data from Phase I
  • First patient treated in the Phase I extension study

fimaVACC

  • Tolerability of the vaccination technology established – awaiting initial results on overall T-cell responses

fimaNAc

  • RXi Pharmaceuticals collaboration expanded into the field of immuno-oncology
  • Top-10 pharma collaboration extended and entered into in vivo studies

Corporate

  • Dr Hans Olivecrona appointed as Chief Medical Officer
  • Completed the fully underwritten rights issue of NOK 70 million
  • Awarded up to NOK 14.3 million in public grants for further development of the vaccination platform

 

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACCapplies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising Field.

 

Source: PCI Biotech

Come learn more about cancer

The Radium Hospital Research Foundation is part of the Oslo Innovation Week and Forskningsdagene with no less than three seminars on cancer together with the Norwegian Cancer Society, Oslo Cancer Cluster and IBM Norge

 

Come join us for updates from a broad range of Nordic experts on three vital topics related to cancer; the threat from antibiotic resistance, past and future innovations within cancer treatment and how Big Data may transform the way cancer treatments are developed. All seminars are free and open for all.

 

Wednesday 27.september 8:00 – 10:30 (am)
Breakfast meeting on “Antibiotic resistance and cancer”

Cancer patients need antibiotics to survive treatment. However, on the basis of some preliminary investigations, the knowledge of how antibiotic resistance will affect cancer treatment is limited.

Antibiotic resistance is considered one of the world’s biggest threats to public health. On a global scale, antibiotic resistance could mean 10 million annual deaths in the year 2030 according to WHO.

 

Wednesday 27. september 17:00 – 21:00 (pm)
Evening seminar on “Cancer innovation and benefit for patients”

Globally, nearly 1 in 6 deaths is due to cancer. The number of new cases is expected to rise by about 70% over the next 2 decades, according to the World Health Organisation, WHO. Even though the future may look look grim, more people than ever survive cancer due to new innovations within diagnostics, treatment and the use of technology.

Spend some time with us in the Norwegian Cancer Society’s Science Centre to get popular scientific, down to earth explanations from Nordic experts on what breakthroughs we will see within cancer care and treatment. We urge the audience to ask questions, comment and discuss with the presenters.

This event is supported by the Research Council of Norway.

 

Thursday 28.september 8:00 – 10:30 (am)
How Big Data may transform the development of cancer treatments

In this seminar we address how Big Data and data analytics may transform the way cancer treatments are developed. Is the use and implementation of technology based on Big Data the key to treat cancer in the near future? What are the benefit for the cancer patients? How may start-ups contribute? Can Norway adopt the Finnish model?

Representatives from Innovation Norway and Research Council in Norway and and the private sector, will debate how the public and private sector may work together to maximize the potential Big Data represents to drive innovations within the cancer field.

 

 

Vi er på Arendalsuka

Jónas Einarsson, administrerende direktør i Radiumhospitalets Forskningsstiftelse skal delta på tre debatter under Arendalsuka.

Det er viktige og aktuelle temaer som kliniske studier, et todelt helsevesen og norske kreftpasienters tilgang til den best mulige kreftbehandling, som Einarsson skal være med å debattere.

Hør Einarsson her i Arendal: 

Sustainable, Innovative Healthcare
Tirsdag 15. aug kl 15 – 16:30 på Clarion Hotel Tyholmen

Et bredt panel skal her diskutere hvordan vi kan oppnå et bærekraftig helsevesen, ikke kun i Norge, men også internasjonalt.
Program og mer info finner du her.

 

Kliniske studier i Norge
Torsdag 17. aug kl 9:00 – 11:00 på Arendal sykehus

Dagens Medisin Arena på Arendal sykehus tar for seg status for kliniske studier i Norge og presenterer blant annet en ny rapport om kliniske helseforskning i Norge.
Program og mer info finner du her.

 

Et Columbi egg for folkehelsa og velferdssamfunnet
Torsdag 17.august kl 11:00 – 12:00 på Blom restaurant

Seminaret skal diskutere hvordan legemiddelnæringen kan bidra positivt til både økt sysselsetting og innovasjon i helsevesenet i en framtid hvor den norske velferdsmodellen er under press.
Program og mer info finner du her.

 

Vi tvitrer fra alle debattene – følg oss på Twitter på @radforsk.

 

 

 

 

 

Oncoimmunity granted NOK 300,000 from Innovation Norway

OncoImmunity provides innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers.


Oncoimmunity is one of Radium Hospital Research Foundation´s portfolio companies. The company is co-localised with the Foundation in the incubator in Oslo Cancer Cluster Innovation Park.


One of the major challenges to overcome is the accurate identification of immunogenic peptides in the tumor, and their precise constellation on a personalized vaccine. In this project OncoImmunity and partners were granted NOK 300.000,- to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.

In this project OncoImmunity and partners were granted NOK 300.000,- to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.

CEO Jónas Einarsson in E24

The financial web page E24 has interviewed CEO Jónas Einarsson about the Radium Hospital Research Foundation.

The article is named *From the laboratory to rocket on the stock exchange – he turns medicine to gold.* Here Einarsson talks about how the Foundation works to commercialize cancer research and how he believes that all the Foundation`s portfolio companies have the potential to become as succesful as Algeta.